Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer - Summary - MDSpire
From the Journals
Conference News

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

Share

The combination of enfortumab vedotin-ejfv and pembrolizumab has emerged as the first-line standard treatment for locally advanced or metastatic urothelial carcinoma. As shown in the phase III KEYNOTE-B15/EV-304 study, this approach significantly enhances event-free and overall survival rates, alongside an increased pathologic complete response in muscle-invasive bladder cancer patients qualified for cisplatin-based chemotherapy. Findings were presented by Dr. Matthew D. Galsky at the 2026 ASCO Genitourinary Cancers Symposium, confirming its efficacy as a perioperative treatment option.

Original Source(s)

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

  • by Jo Cavallo

  • April 17, 2026

Related Content

Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape

Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch

  • April 17, 2026

  • 6 min
Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...

Dana-Farber Research News 04.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.

  • by

  • April 15, 2026

  • 22 min